Conference Coverage ASCO GI 2020 Highlights

The latest translational and therapeutic developments in GI cancer pathogenesis and treatment, and implications on individualized clinical decision-making coming out of the ASCO GI 2020 conference. How will emerging research affect ongoing clinical trials, development of new compounds, and future treatment paradigms?

Faculty Chair

Axel Grothey, MD

West Cancer Center, TN, USA

ASCO GI 2020 Topics Covered in the Report

Hepatocellular

    • Abstract 478: Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. First Author: Thomas Yau
    • Abstract 476: Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). First Author: Peter R. Galle, MD
    • Abstract 549: Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2). First Author: Masatoshi Kudo, MD, PhD
    • Abstract 483: CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). First Author: Julien Edeline, MCU-PH
    • Abstract 518: Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). First Author: Masatoshi Kudo, MD, PhD
    • Abstract 542: Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial. First Author: Ho Yeong Lim, MD, PhD

Pancreatic

    • Abstract 639: A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation. First Author: Eileen Mary O’Reilly, MD
    • Abstract 648: Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. First Author: Michael Hall, MD, MS
    • Abstract 637: Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA). First Author: J. Randolph Hecht, MD
    • Abstract 638: HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). First Author: Margaret A. Tempero, MD, FASCO
    • Abstract 704: Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns. First Author: Vaibhav Sahai, MBBS, MS

Gastroesophageal

    • Abstract 282: Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study. First Author: David Cunningham, MD
    • Abstract 278: Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). First Author: Markus H. Moehler, MD, PhD
    • Abstract 383: A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data. First Author: Li-Tzong Chen, MD, PhD
    • Abstract 427: Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies. First Author: Zev A. Wainberg, MD
    • Abstract 823: Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST). First Author: Tsuyoshi Takahashi, PhD, MD
    • Abstract 824: Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. First Author: Jordan Berlin, MD, FASCO

Faculty Members

Dirk Arnold, MD, PhD
University of Hamburg and Asklepios Tumor Center
Hamburg, Germany

Scott Kopetz, MD, PhD
MD Anderson Cancer Center
Houston, TX, USA

Cathy Eng, MD
Vanderbilt Cancer Center
Nashville, TN, USA

Lakshmi Rajdev, MD
Montefiore Einstein Center for Cancer Care
New York City, NY, USA

Explore Available and Upcoming Insight Reports

View Reports